CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma Eric Smith, Sean M. Devlin, Satyajit.

Slides:

Advertisements

Similar presentations

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation Sarah J. Kizilbash, Clifford E. Kashtan,

Advertisements

Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host.

Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates Ian Nivison-Smith, Judy M. Simpson, Anthony.

Prognostic Importance of Functional Capacity for Pre-Transplant Risk Assessment Among Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

A Phase 1/2 Trial of Carfilzomib + High Dose Melphalan Conditioning for Auto-HCT Followed by Carfilzomib Maintenance for Patients with Relapsed Multiple.

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma Taewoong Choi, Murali K. Kodali, Wen-Kai Weng

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

A Response Adapted Approach to Induction Treatment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Gunjan L. Shah,

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis.

Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia Paul M. Armistead, Marcos.

Gain of Chromosome 1q Portends Worse Prognosis in Multiple Myeloma Patients Treated with Novel Agent Based Induction Regimens Even after Autologous Transplantation

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma Gaurav C. Parikh, Ali Imran Amjad, Rima.

Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation David Nachbaur, Petra Schumacher,

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer Brigitta Omazic, Mats Remberger, Lisbeth Barkholt, Gunnar.

Significance of Ethnicity in the Risk of Acute Graft-versus-Host Disease and Leukemia Relapse after Unrelated Donor Hematopoietic Stem Cell Transplantation

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Betty T. Tran, Abigail Halperin, Jason W. Chien

Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic.

Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in Allogeneic Stem Cell Transplantation: Systematic Literature Review and Network.

Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission Jennifer L. Holter.

Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes Koen Van Besien,

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma Jessica Rueff, Michael Medinger,

Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide.

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

Biology of Blood and Marrow Transplantation

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

John Kuruvilla, John D. Shepherd, Heather J. Sutherland, Thomas J

Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies Robert.

Infections Are the Major Cause of Non Relapse Mortality (NRM) after T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplantation for Advanced.

Graft-Versus Host Disease (GVHD Status and Severity Mediate Late Effects of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in a 1-Year Landmark.

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Kamal Kant Singh Abbi, Junting Zheng, Sean M

David J. Chung, MD, PhD, Katherine B. Pronschinske, Justin A

Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma:

Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study.

Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High- Risk Acute Lymphoblastic Leukemia Samer A. Srour, Denái R. Milton,

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation Sarah J. Kizilbash, Clifford E. Kashtan,

Biology of Blood and Marrow Transplantation

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival Victor H. Jimenez-Zepeda,

Resolved Hepatitis B Virus Infection Is Not Associated with Worse Outcome after Allogeneic Hematopoietic Stem Cell Transplantation Carlos A. Ramos, Rima.

What is quality in a transplant program?

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.

Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome Scott R. Solomon, Bipin N. Savani, Richard.

Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy.

Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based.

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Allogeneic Peripheral Blood Stem Cell Transplantation is a Promising and Safe Choice for the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia,

High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin Lymphoma Adrian J.C. Bloor, Kirsty.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Presentation transcript:

CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma Eric Smith, Sean M. Devlin, Satyajit Kosuri, Evelyn Orlando, Heather Landau, Alex M. Lesokhin, David J. Chung, Hani Hassoun, Nikoletta Lendvai, Ola Landgren, Sergio Giralt, Ajai Chari, Sundar Jagannath, Guenther Koehne Biology of Blood and Marrow Transplantation Volume 22, Issue 2, Pages 258-267 (February 2016) DOI: 10.1016/j.bbmt.2015.08.025 Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Overall and progression-free survival of 44 patients with multiply relapsed MM undergoing CD34-selected HSCT. Biology of Blood and Marrow Transplantation 2016 22, 258-267DOI: (10.1016/j.bbmt.2015.08.025) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Overall (A) and progression-free (B) survival based on lines of treatment before CD34-selected HSCT. For these analyses, auto-SCT followed by maintenance therapy and tandem auto-SCT plus maintenance therapy were calculated as a single line of treatment as detailed in Table 1. Biology of Blood and Marrow Transplantation 2016 22, 258-267DOI: (10.1016/j.bbmt.2015.08.025) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Overall and progression-free survival based on disease status before CD34-selected HSCT; partial remission (PR) versus very good partial remission (VGPR)/complete remission (CR). Biology of Blood and Marrow Transplantation 2016 22, 258-267DOI: (10.1016/j.bbmt.2015.08.025) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Overall (A) and progression-free (B) survival based on presence (n = 13) or absence (n = 31) of extramedullary manifestation before CD34-selected HSCT. Biology of Blood and Marrow Transplantation 2016 22, 258-267DOI: (10.1016/j.bbmt.2015.08.025) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Acute GVHD and non-relapse mortality (NRM). (A) Acute GVHD (grade II-IV) to days +180 post CD34-selected HSCT, (B) NRM post CD34-selected HSCT and (C), NRM based on disease status (PR; n = 21) or (VGPR/CR; n = 23) before CD34-selected HSCT. Biology of Blood and Marrow Transplantation 2016 22, 258-267DOI: (10.1016/j.bbmt.2015.08.025) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions